Treatment of lymphangiomas with OK-432 (Picibanil) sclerotherapy: a prospective multi-institutional trial

Chantal M Giguère; Nancy M Bauman; Yutaka Sato; Diane K Burke; John H Greinwald; Seth Pransky; Peggy Kelley; Keith Georgeson; Richard J H Smith

doi:10.1001/archotol.128.10.1137

Back

Treatment of lymphangiomas with OK-432 (Picibanil) sclerotherapy: a prospective multi-institutional trial

Journal article

Open access

Peer reviewed

Treatment of lymphangiomas with OK-432 (Picibanil) sclerotherapy: a prospective multi-institutional trial

Chantal M Giguère, Nancy M Bauman, Yutaka Sato, Diane K Burke, John H Greinwald, Seth Pransky, Peggy Kelley, Keith Georgeson and Richard J H Smith

Archives of otolaryngology--head & neck surgery, Vol.128(10), pp.1137-1144

10/2002

DOI: 10.1001/archotol.128.10.1137

PMID: 12365884

Files and links (1)

url

https://doi.org/10.1001/archotol.128.10.1137View

Published (Version of record) Open Access

Abstract

To describe and to determine the robustness of our study evaluating the efficacy of OK-432 (Picibanil) as a therapeutic modality for lymphangiomas. Prospective, randomized trial and parallel-case series at 13 US tertiary care referral centers. Thirty patients diagnosed as having lymphangioma. Ages in 25 ranged from 6 months to 18 years. Twenty-nine had lesions located in the head-and-neck area. Every patient received a 4-dose injection series of OK-432 scheduled 6 to 8 weeks apart unless a contraindication existed or a complete response was observed before completion of all injections. A control group was observed for 6 months. Successful outcome of therapy was defined as a complete or a substantial (>60%) reduction in lymphangioma size as determined by calculated lesion volumes on computed tomographic or magnetic resonance imaging scans. Overall, 19 (86%) of the 22 patients with predominantly macrocystic lymphangiomas had a successful outcome. OK-432 should be efficacious in the treatment of lymphangiomas. Our study design is well structured to clearly define the role of this treatment agent.

Prospective Studies

Humans

Middle Aged

Child, Preschool

Infant

Male

Tomography, X-Ray Computed

Antineoplastic Agents - therapeutic use

Antineoplastic Agents - administration & dosage

Lymphangioma - diagnostic imaging

Antineoplastic Agents - adverse effects

Lymphangioma - therapy

Aged, 80 and over

Adult

Female

Child

Lymphangioma - pathology

Head and Neck Neoplasms - diagnostic imaging

Head and Neck Neoplasms - therapy

Treatment Outcome

Sclerotherapy - adverse effects

Head and Neck Neoplasms - pathology

Magnetic Resonance Imaging

Adolescent

Aged

Picibanil - administration & dosage

Picibanil - adverse effects

Picibanil - therapeutic use

Details

Title: Subtitle: Treatment of lymphangiomas with OK-432 (Picibanil) sclerotherapy: a prospective multi-institutional trial
Creators: Chantal M Giguère - Department of Otolaryngology, The University of Iowa, Iowa City 52242, USA
Nancy M Bauman
Yutaka Sato
Diane K Burke
John H Greinwald
Seth Pransky
Peggy Kelley
Keith Georgeson
Richard J H Smith
Resource Type: Journal article
Publication Details: Archives of otolaryngology--head & neck surgery, Vol.128(10), pp.1137-1144
DOI: 10.1001/archotol.128.10.1137
PMID: 12365884
NLM abbreviation: Arch Otolaryngol Head Neck Surg
ISSN: 0886-4470
eISSN: 1538-361X
Publisher: American Medical Association; United States
Language: English
Date published: 10/2002
Academic Unit: Roy J. Carver Department of Biomedical Engineering; Radiology; Molecular Physiology and Biophysics; Anatomy and Cell Biology; Stead Family Department of Pediatrics; Iowa Neuroscience Institute; Otolaryngology; Internal Medicine
Record Identifier: 9984006453402771

Metrics

64 Record Views

157 Times Cited - Web of Science